<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="iso-abbrev">Cold Spring Harb Mol Case Stud</journal-id>
<journal-id journal-id-type="hwp">cshmcs</journal-id>
<journal-id journal-id-type="pmc">cshmcs</journal-id>
<journal-id journal-id-type="publisher-id">cshmcs</journal-id>
<journal-title-group>
<journal-title>Cold Spring Harbor Molecular Case Studies</journal-title>
</journal-title-group>
<issn pub-type="epub">2373-2873</issn>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30446579</article-id>
<article-id pub-id-type="pmc">6371744</article-id>
<article-id pub-id-type="doi">10.1101/mcs.a003483</article-id>
<article-id pub-id-type="medline">MCS003483Tan</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A newly identified mutation in the <italic>PEX26</italic> gene is associated with a milder form of Zellweger spectrum disorder</article-title>
<alt-title alt-title-type="left-running">New mutation of <italic>PEX26</italic> causing only hearing loss</alt-title>
<alt-title alt-title-type="right-running">New mutation of <italic>PEX26</italic> causing only hearing loss</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Tanaka</surname>
<given-names>Akemi J.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="author-notes" rid="FN1">7</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Okumoto</surname>
<given-names>Kanji</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
<xref ref-type="aff" rid="af3">3</xref>
<xref ref-type="author-notes" rid="FN1">7</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Tamura</surname>
<given-names>Shigehiko</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
<xref ref-type="aff" rid="af4">4</xref>
<xref ref-type="author-notes" rid="FN1">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abe</surname>
<given-names>Yuichi</given-names>
</name>
<xref ref-type="aff" rid="af5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hirsch</surname>
<given-names>Yoel</given-names>
</name>
<xref ref-type="aff" rid="af6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deng</surname>
<given-names>Liyong</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ekstein</surname>
<given-names>Joseph</given-names>
</name>
<xref ref-type="aff" rid="af6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chung</surname>
<given-names>Wendy K.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fujiki</surname>
<given-names>Yukio</given-names>
</name>
<xref ref-type="aff" rid="af5">5</xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label>Department of Pediatrics, Columbia University Medical Center, New York, New York 10019, USA;</aff>
<aff id="af2"><label>2</label>Department of Biology, Faculty of Sciences, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan;</aff>
<aff id="af3"><label>3</label>Graduate School of Systems Life Sciences, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan;</aff>
<aff id="af4"><label>4</label>Faculty of Arts and Science, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan;</aff>
<aff id="af5"><label>5</label>Division of Organelle Homeostasis, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan;</aff>
<aff id="af6"><label>6</label>Dor Yeshorim, The Committee for Prevention of Jewish Genetic Diseases, Brooklyn, New York 11211, USA</aff>
<author-notes>
<fn id="FN1">
<label>7</label>
<p>A.J.T., K.O., and S.T. equally contributed to this work.</p>
</fn>
<corresp>Corresponding author: <email>yfujiki@kyudai.jp</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>2</month>
<year>2019</year>
</pub-date>
<volume>5</volume>
<issue>1</issue>
<elocation-id>a003483</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>
<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.cshlp.org/site/misc/terms.xhtml">© 2019 Tanaka et al.; Published by Cold Spring Harbor Laboratory Press</ext-link>
</copyright-statement>
<copyright-year>2019</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial License</ext-link>, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="MCS003483Tan.pdf"></self-uri>
<abstract>
<p>Using clinical exome sequencing (ES), we identified an autosomal recessive missense variant, c.153C&gt;A (p.F51L), in the peroxisome biogenesis factor 26 gene (<italic>PEX26</italic>) in a 19-yr-old female of Ashkenazi Jewish descent who was referred for moderate to severe hearing loss. The proband and three affected siblings are all homozygous for the c.153C&gt;A variant. Skin fibroblasts from this patient show normal morphology in immunostaining of matrix proteins, although the level of catalase was elevated. Import rate of matrix proteins was significantly decreased in the patient-derived fibroblasts. Binding of Pex26-F51L to the AAA ATPase peroxins, Pex1 and Pex6, is severely impaired and affects peroxisome assembly. Moreover, Pex26 in the patient's fibroblasts is reduced to ∼30% of the control, suggesting that Pex26-F51L is unstable in cells. In the patient's fibroblasts, peroxisome-targeting signal 1 (PTS1) proteins, PTS2 protein 3-ketoacyl-CoA thiolase, and catalase are present in a punctate staining pattern at 37°C and in a diffuse pattern at 42°C, suggesting that these matrix proteins are not imported to peroxisomes in a temperature-sensitive manner. Analysis of peroxisomal metabolism in the patient's fibroblasts showed that the level of docosahexaenoic acid (DHA) (C22:6n-3) in ether phospholipids is decreased, whereas other lipid metabolism, including peroxisomal fatty acid β-oxidation, is normal. Collectively, the functional data support the mild phenotype of nonsyndromic hearing loss in patients harboring the F51L variant in <italic>PEX26</italic>.</p>
</abstract>
<kwd-group>
<kwd>sensorineural hearing impairment</kwd>
<kwd>very long chain fatty acid accumulation</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>Scientific Research</funding-source>
<award-id>JP26116007</award-id>
<award-id>JP15K21743</award-id>
<award-id>JP17H03675</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>
<institution-wrap>
<institution>Takeda Science Foundation </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100007449</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group id="funding-3">
<funding-source>
<institution-wrap>
<institution>Naito Foundation </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100007428</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group id="funding-4">
<funding-source>
<institution-wrap>
<institution>Japan Foundation for Applied Enzymology </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100008695</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<award-group id="funding-5">
<funding-source>Novartis Foundation (Japan) for the Promotion of Science</funding-source>
</award-group>
<award-group id="funding-6">
<funding-source>JPB Foundation and Simons Foundation</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="16"></page-count>
</counts>
</article-meta>
</front>
<body><sec id="s1" sec-type="introduction"><title>INTRODUCTION</title><p>Peroxisomes are single membrane–bounded organelles that function in numerous metabolic pathways, including β-oxidation of very long-chain fatty acids (VLCFA), detoxification of hydrogen peroxides, and synthesis of ether phospholipids and bile acids (<xref ref-type="bibr" rid="MCS003483TANC42">Wanders and Waterham 2006</xref>). Impairment of peroxisome biogenesis causes peroxisome biogenesis disorders (PBDs), termed Zellweger spectrum disorders (ZSDs), including Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD), and rhizomelic chondrodysplasia punctata types 1 and 5 (<xref ref-type="bibr" rid="MCS003483TANC13">Gould and Valle 2000</xref>; <xref ref-type="bibr" rid="MCS003483TANC9">Fujiki et al. 2006</xref>; <xref ref-type="bibr" rid="MCS003483TANC2">Barøy et al. 2015</xref>). Fourteen <italic>PEX</italic> genes, including peroxisome biogenesis factor 26 (<italic>PEX26</italic>), have been identified as the causes of PBDs (<xref ref-type="bibr" rid="MCS003483TANC43">Waterham and Ebberink 2012</xref>; Fujiki et al. 2014; <xref ref-type="bibr" rid="MCS003483TANC8">Fujiki 2016</xref>).</p><p>The <italic>PEX26</italic> gene (OMIM# 608666) encodes the peroxisome assembly factor termed peroxin Pex26, which is involved in peroxisomal matrix protein import (<xref ref-type="bibr" rid="MCS003483TANC21">Matsumoto et al. 2003a</xref>). Biallelic pathogenic variants in the <italic>PEX26</italic> gene are associated with ZSDs of complementation group (CG) 8, which have variable clinical manifestations ranging from a severe, lethal phenotype in ZS to NALD (PBD7A; OMIM# 615872), and the least severe IRD (PBD7B; OMIM# 614873). Patients with ZS have significant hypotonia with poor feeding, distinctive facial features, seizures, and hepatic dysfunction and typically do not live past the first year of life. Older children with ZS show significant developmental delay with retinal dystrophy and sensorineural hearing loss. The phenotypes of NALD and IRD are variable and milder than ZS and may include developmental delay, hypotonia, hearing loss, visual impairment, hemorrhage, and intracranial bleeding. Pathogenic variants in <italic>PEX26</italic> have been identified in patients with ZSD (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003483/-/DC1">Supplemental Table S1</ext-link>; <xref ref-type="bibr" rid="MCS003483TANC21">Matsumoto et al. 2003a</xref>,<xref ref-type="bibr" rid="MCS003483TANC22">b</xref>; <xref ref-type="bibr" rid="MCS003483TANC33">Steinberg et al. 2004</xref>, <xref ref-type="bibr" rid="MCS003483TANC34">2006</xref>; <xref ref-type="bibr" rid="MCS003483TANC45">Weller et al. 2005</xref>; <xref ref-type="bibr" rid="MCS003483TANC11">Furuki et al. 2006</xref>; <xref ref-type="bibr" rid="MCS003483TANC6">Ebberink et al. 2011</xref>; <xref ref-type="bibr" rid="MCS003483TANC26">Neuhaus et al. 2017</xref>; <xref ref-type="bibr" rid="MCS003483TANC35">Stowe and Agarwal 2017</xref>). Here, we describe an Ashkenazi Jewish family with four affected individuals who are all homozygous for a predicted deleterious missense variant in <italic>PEX26</italic> and who all share a phenotype of nonsyndromic sensorineural hearing loss with no other symptoms of ZSD.</p></sec><sec id="s2" sec-type="results"><title>RESULTS</title><sec id="s2a"><title>Clinical Presentation and Family History</title><p>The proband is a 19-yr-old female who was referred for moderate to severe hearing loss and a family history significant for three siblings with hearing loss. The proband and affected siblings are otherwise healthy, and all had normal prenatal and postnatal clinical courses and neurodevelopment.</p><p>Clinical exome sequencing (ES) was performed at GeneDx (Gaithersburg, MD, USA) (<ext-link ext-link-type="uri" xlink:href="http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003483/-/DC1">Supplemental Table S2</ext-link>) as previously described (Tanaka et al. 2017) on the proband (<xref ref-type="fig" rid="MCS003483TANF1">Fig. 1</xref>A, Individual 3), both parents, and one affected sibling (Individual 1) from a family with four affected individuals with nonsyndromic hearing loss and three unaffected siblings (Individuals 2, 4, and 7). An autosomal recessive missense variant in <italic>PEX26</italic> was identified as potentially causative for the nonsyndromic hearing loss phenotype (<xref ref-type="table" rid="MCS003483TANTB1">Table 1</xref>). The c.153C&gt;A (F51L) variant in the <italic>PEX26</italic> gene (<xref ref-type="fig" rid="MCS003483TANF1">Fig. 1</xref>B) was confirmed by Sanger sequencing to be homozygous in the proband and the affected sibling and heterozygous in each parent (<xref ref-type="fig" rid="MCS003483TANF1">Fig. 1</xref>C, left panels; <xref ref-type="table" rid="MCS003483TANTB2">Table 2</xref>). The mutation was also identified by reverse transcription (RT)-PCR product using poly(A)<sup>+</sup> RNA from fibroblasts of the proband (Individual 3), termed Pex26-F51L (<xref ref-type="fig" rid="MCS003483TANF1">Fig. 1</xref>C, right panels). The proband's affected younger brother (Individual 6) and sister (Individual 5) were analyzed only for the c.153C&gt;A <italic>PEX26</italic> variant and were homozygous for the A allele. The genotypes for the unaffected siblings are shown in <xref ref-type="fig" rid="MCS003483TANF1">Figure 1</xref>.</p><fig id="MCS003483TANF1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Mutation analysis of <italic>PEX26</italic> from individuals with nonsyndromic hearing loss. (<italic>A</italic>) Pedigree of a family with F51L mutation in <italic>PEX26</italic>. The affected proband (arrow) is homozygous for the F51L mutation. (<italic>B</italic>) Schematic representation of human Pex26. (Numbers) amino acid residues of Pex26, (*) F51L mutation identified in <italic>A</italic>, (shaded box) transmembrane segment; the regions at 12–77 and 78–85 in the amino-terminal region interact with the Pex1–Pex6 complex and Pex14, respectively. (<italic>C</italic>) Exome sequencing analysis identified one point mutation of nucleotide C153 (the <italic>A</italic> of the initiator ATG being no. 1) in the codon for Phe51 to <italic>A</italic> in the <italic>PEX26</italic> gene. (<italic>Left</italic>) Sanger electropherograms of control, heterozygous, and homozygous siblings are shown. (<italic>Right</italic>) Mutation analysis was also performed by RT-PCR, in which the mutation of nucleotide C153 to A resulting in F51L was detected in Pex26-F51L fibroblasts. (<italic>Figure and legend continue on following page.</italic>) (<italic>D</italic>) Human mutations in Pex26. Previously identified mutations in Pex26 are marked with missense and nonsense mutations above the protein diagram, and frameshift, truncating, and copy-number variation (CNV) mutations below. (Blue) cytoplasmic domain, (diamonds) other peroxin-interacting domain, (striped lines) transmembrane domains. (<italic>E</italic>) Pex26 sequence alignment. Characteristics of Pex26 are from human studies. Missense mutations are in bold, F51L in red. (Blue highlight) Cytoplasmic domains, (dotted underline) other peroxin-interacting domains, (single underline) transmembrane domains. (Macmu) <italic>Rhesus macaque</italic>, (Loxaf) elephant, (Ailme) giant panda, (Canlf) dog, (Xentr) <italic>Xenopus tropicalis</italic>, (Danre) zebrafish.</p></caption><graphic xlink:href="MCS003483Tan_F1A"></graphic><graphic xlink:href="MCS003483Tan_F1B"></graphic><graphic xlink:href="MCS003483Tan_F1C"></graphic></fig><table-wrap id="MCS003483TANTB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Variant table</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="center" colspan="1" rowspan="1">Chromosome</th><th align="center" colspan="1" rowspan="1">HGVS DNA reference</th><th align="center" colspan="1" rowspan="1">HGVS protein reference</th><th align="center" colspan="1" rowspan="1">Variant type</th><th align="center" colspan="1" rowspan="1">Predicted effect (substitution, deletion, etc.)</th><th align="center" colspan="1" rowspan="1">dbSNP/dbVar ID</th><th align="center" colspan="1" rowspan="1">Genotype (heterozygous/homozygous)</th><th align="center" colspan="1" rowspan="1">ClinVar ID</th><th align="center" colspan="1" rowspan="1">Parent of origin</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic>PEX26</italic></td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">NM_017929.5: c.153C&gt;A</td><td colspan="1" rowspan="1">NP_060399.1: p.Phe51Leu</td><td colspan="1" rowspan="1">Single-nucleotide variant</td><td colspan="1" rowspan="1">Substitution</td><td colspan="1" rowspan="1">rs777633990</td><td colspan="1" rowspan="1">Homozygous</td><td colspan="1" rowspan="1">SCV000804559</td><td colspan="1" rowspan="1">Biparental</td></tr></tbody></table></table-wrap><table-wrap id="MCS003483TANTB2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Clinical phenotype of <italic>PEX26</italic> F51L variant in four affected individuals</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" span="1"/><col align="char" char="." span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Individual</th><th align="center" colspan="1" rowspan="1">Sex</th><th align="center" colspan="1" rowspan="1">Age</th><th align="center" colspan="1" rowspan="1">Prenatal issues</th><th align="center" colspan="1" rowspan="1">Newborn screening</th><th align="center" colspan="1" rowspan="1">Type of hearing loss</th><th align="center" colspan="1" rowspan="1">Age of onset</th><th align="center" colspan="1" rowspan="1">Laterality</th><th align="center" colspan="1" rowspan="1">Degree and configuration</th><th align="center" colspan="1" rowspan="1">Other medical</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">SNHL, mild</td><td colspan="1" rowspan="1">2–3 yr</td><td colspan="1" rowspan="1">Bilateral</td><td colspan="1" rowspan="1">Symmetric</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">SNHL, moderate to severe</td><td colspan="1" rowspan="1">12–24 mo</td><td colspan="1" rowspan="1">Bilateral</td><td colspan="1" rowspan="1">Symmetric</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">SNHL, moderate to severe</td><td colspan="1" rowspan="1">12–24 mo</td><td colspan="1" rowspan="1">Bilateral</td><td colspan="1" rowspan="1">Symmetric</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">SNHL, moderate to severe</td><td colspan="1" rowspan="1">12–24 mo</td><td colspan="1" rowspan="1">Bilateral</td><td colspan="1" rowspan="1">Symmetric</td><td colspan="1" rowspan="1">None</td></tr></tbody></table><table-wrap-foot><fn><p>(SNHL) Sensorineural hearing loss.</p></fn></table-wrap-foot></table-wrap><p>The F51L variant is located in a highly evolutionarily conserved region across species (<xref ref-type="fig" rid="MCS003483TANF1">Fig. 1</xref>D,E) and is predicted to be deleterious by SIFT (<uri xlink:href="http://sift.jcvi.org/">http://sift.jcvi.org/</uri>), Provean (<uri xlink:href="http://provean.jcvi.org/">http://provean.jcvi.org/</uri>), CADD (<uri xlink:href="http://cadd.gs.washington.edu/">http://cadd.gs.washington.edu/</uri>), and MetaSVM (<uri xlink:href="https://omictools.com/">https://omictools.com/</uri> meta-svm-tool) (<xref ref-type="table" rid="MCS003483TANTB3">Table 3</xref>). In our earlier report, we demonstrated that the region of Pex26 protein encompassing residues 12–77 and 78–85 in the amino-terminal region is involved in the interaction with the Pex1–Pex6 complex and Pex14, respectively (<xref ref-type="fig" rid="MCS003483TANF1">Fig. 1</xref>B; <xref ref-type="bibr" rid="MCS003483TANC38">Tamura et al. 2014</xref>). The F51L variant is a rare missense variant that occurs at low frequency in the Genome Aggregation Databases (gnomAD) (allele frequency = 2.239 × 10<sup>−5</sup>, 4/178,684 total individuals) and is absent in the gnomAD genomes and NHLBI Exome Variant Server (EVS) databases, indicating that it is not a common variant in the populations represented by these databases. The four individuals identified in gnomAD exomes heterozygous for the F51L variant are of Ashkenazi Jewish (AJ) descent, and F51L appears to be a founder mutation with an estimated carrier frequency of 1/1878 in the AJ population (<uri xlink:href="https://ibd.broadinstitute.org/">https://ibd.broadinstitute.org/</uri>).</p><table-wrap id="MCS003483TANTB3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Pathogenicity and allele frequency of Pex26-F51L variant</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="char" span="1"/><col align="char" span="1"/><col align="left" span="1"/><col align="char" span="1"/><col align="char" span="1"/><col align="char" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="center" colspan="1" rowspan="1">Chromosome</th><th align="center" colspan="1" rowspan="1">Chromosome coordinates (GRCh37/hg19)</th><th align="center" colspan="1" rowspan="1">Transcript</th><th align="center" colspan="1" rowspan="1">Nucleotide change</th><th align="center" colspan="1" rowspan="1">Amino acid change</th><th align="center" colspan="1" rowspan="1">SIFT</th><th align="center" colspan="1" rowspan="1">Provean</th><th align="center" colspan="1" rowspan="1">PolyPhen-2</th><th align="center" colspan="1" rowspan="1">MetaSVM</th><th align="center" colspan="1" rowspan="1">CADD13</th><th align="center" colspan="1" rowspan="1">Allele frequency in gnomAD</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic>PEX26</italic></td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">18561295</td><td colspan="1" rowspan="1">PEX26:NM_017929.5</td><td colspan="1" rowspan="1">c.153C&gt;A</td><td colspan="1" rowspan="1">p.Phe51Leu</td><td colspan="1" rowspan="1">Damaging (0.00)</td><td colspan="1" rowspan="1">Damaging (−4.56)</td><td colspan="1" rowspan="1">Probably damaging (0.999)</td><td colspan="1" rowspan="1">Damaging (0.4751)</td><td colspan="1" rowspan="1">23.0</td><td colspan="1" rowspan="1">0.00002239<sup>a</sup></td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>4/178684, no homozygotes, mean exomes coverage 53.7×.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Peroxisomal Protein Import Is Morphologically Normal in Pex26-F51L Fibroblasts</title><p>Using immunofluorescence microscopy of control fibroblasts, catalase (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>A) as well as peroxisome-targeting signal 1 (PTS1) proteins including acyl-CoA oxidase (AOx) and a peroxisome-targeting signal 2 (PTS2) protein, alkyldihydroxyacetonephosphate synthase (ADAPS), were detected in punctate structures that merged with Pex14 (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>B), showing normal import of both PTS1 and PTS2 types of matrix proteins into peroxisomes. Earlier reports showed that fibroblasts derived from CG8 patients with ZS and with NALD and IRD demonstrate complete and partial defects in peroxisomal import of catalase and a PTS2 protein, 3-ketoacyl-CoA thiolase (TH), respectively, although PTS1 proteins were similarly discernible in peroxisomes as in control fibroblasts and those from CG8 patients with ZS, NALD, and IRD (<xref ref-type="bibr" rid="MCS003483TANC22">Matsumoto et al. 2003b</xref>; <xref ref-type="bibr" rid="MCS003483TANC11">Furuki et al. 2006</xref>). In Pex26-F51L fibroblasts, peroxisomal localization of catalase was observed (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>D–F) similar to control fibroblasts (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>A–C). PTS1 proteins (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>G–I), AOx (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>J–L) and ADAPS (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>M–O) were likewise localized to peroxisomes in fibroblasts from the proband as in control fibroblasts. These results suggest the biochemical phenotype is milder compared to that reported in CG8 fibroblasts associated with NALD and IRD, showing little to no detectable defect in peroxisomal matrix protein import as assessed by morphological analysis.</p><fig id="MCS003483TANF2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Morphological analysis of fibroblasts derived from a patient with <italic>PEX26</italic> mutation. Control fibroblasts (<italic>A–C</italic>) and Pex26-F51L fibroblasts from a <italic>PEX26</italic>-defective patient (<italic>D–O</italic>) were immunostained with antibodies to Pex14 (<italic>B</italic>,<italic>E</italic>,<italic>H</italic>,<italic>K</italic>,<italic>N</italic>) and peroxisomal matrix proteins indicated in <italic>top</italic> panels (<italic>A</italic>,<italic>D</italic>,<italic>G</italic>,<italic>J</italic>,<italic>M</italic>). Merged views are shown in <italic>bottom</italic> panels (<italic>C</italic>,<italic>F</italic>,<italic>I</italic>,<italic>L</italic>,<italic>O</italic>). (AOx) Acyl-CoA oxidase, (ADAPS) alkyl-dihydroxyacetonephosphate synthase. Scale bar, 10 µm.</p></caption><graphic xlink:href="MCS003483Tan_F2"></graphic></fig></sec><sec id="s2c"><title>Unstable Pex26 in Pex26-F51L Fibroblasts Affects Catalase Protein Level and Intracellular Distribution</title><p>Next, peroxisome biogenesis in Pex26-F51L fibroblasts was investigated by immunoblot analysis. In mammals, several PTS1 proteins such as a 75-kDa polypeptide A-chain of full-length AOx and a precursor form of sterol carrier protein x (SCPx), are proteolytically processed in the peroxisomal matrix, resulting in 53-kDa B-chain and 22-kDa C-chain components of AOx and a mature form of SCPx, respectively (<xref ref-type="bibr" rid="MCS003483TANC24">Miyazawa et al. 1989</xref>; <xref ref-type="bibr" rid="MCS003483TANC32">Shimozawa et al. 1992</xref>; <xref ref-type="bibr" rid="MCS003483TANC31">Otera et al. 2001</xref>). Processing of AOx and SCPx was observed to a similar extent in both control fibroblasts and Pex26-F51L cells (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>A, left panels). Protein levels of other PTS1 proteins, dihydroxyacetonephosphate acyltransferase (DHAPAT) and peroxisomal Lon protease (PsLon), were also indistinguishable between control fibroblasts and Pex26-F51L fibroblasts (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>A, left panels). Precursors of PTS2 proteins, TH and ADAPS, are converted to their respective mature forms by cleaving the amino-terminal PTS2 presequences in peroxisomes (<xref ref-type="bibr" rid="MCS003483TANC29">Osumi et al. 1991</xref>; <xref ref-type="bibr" rid="MCS003483TANC37">Swinkels et al. 1991</xref>; <xref ref-type="bibr" rid="MCS003483TANC5">de Vet et al. 1998</xref>; <xref ref-type="bibr" rid="MCS003483TANC15">Honsho et al. 2008</xref>). Only mature forms of TH and ADAPS were likewise discernible in both control fibroblasts and Pex26-F51L fibroblasts (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>A). These phenotypes correlated well with the observation that full-length trypsin domain-containing 1 (Tysnd1), the enzymatically active form of a PTS1 protein catalyzing both processing of PTS1 proteins and cleavage of PTS2 proteins (<xref ref-type="bibr" rid="MCS003483TANC20">Kurochkin et al. 2007</xref>; <xref ref-type="bibr" rid="MCS003483TANC27">Okumoto et al. 2011</xref>), was detectable at a similar level in both control and Pex26-F51L fibroblasts (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>A, right panels). These results strongly suggest that peroxisomal matrix protein import, including both PTS1 and PTS2 proteins, is largely normal in Pex26-F51L fibroblasts, consistent with cell-immunostaining analysis (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>).</p><fig id="MCS003483TANF3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Biogenesis of peroxisomes in fibroblasts derived from a patient with defective <italic>PEX26</italic>. (<italic>A</italic>) Whole-cell lysates of control fibroblasts and patient-derived <italic>PEX26</italic>-deficient fibroblasts (Pex26-F51L) were analyzed by SDS-PAGE and immunoblotting with antibodies indicated on the <italic>left</italic>. B and C in immunoblot with anti-AOx antibody indicate B- and C-chains derived from intraperoxisomal processing of the full-length A-chain, respectively. F and C in immunoblot with anti-Tysnd1 antibody show the full-length and the self-cleaved, carboxy-terminal portion of Tysnd1, respectively. (P and M) Precursor and mature forms, respectively. Stars show nonspecific bands. (<italic>B</italic>) Protein level of endogenous Pex26 in Pex26-F51L fibroblasts. Organelle fractions prepared from postnuclear fraction of control fibroblasts and Pex26-F51L fibroblasts were analyzed by SDS-PAGE and immunoblotting with antibodies to Pex26 and an ER membrane protein P450 reductase (P450r).</p></caption><graphic xlink:href="MCS003483Tan_F3"></graphic></fig><p>Furthermore, there was no difference between Pex26-F51L fibroblasts and control fibroblasts in the expression of peroxisomal membrane proteins (PMPs) such as PMP70, peroxins Pex14 and Pex13, and fatty acyl-CoA reductase 1 (Far1) (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>A), indicative of the normal import of PMPs in the proband. Interestingly, we noted that catalase was significantly elevated in Pex26-F51L fibroblasts (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>A). Moreover, Pex26 protein levels were reduced to ∼30% of control fibroblasts as quantified by densitometry (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>B), suggesting that the c.153C&gt;A mutation in <italic>PEX26</italic> reduces the stability of Pex26. It is possible that the instability of Pex26 in Pex26-F51L fibroblasts causes a mild phenotype representing morphologically undetectable defects in peroxisome biogenesis including normal peroxisomal protein import.</p></sec><sec id="s2d"><title>Temperature-Sensitive Phenotype and Decreased Peroxisomal Protein Import in Pex26-F51L Cells</title><p>In Pex26-F51L fibroblasts, catalase, typical PTS1 proteins including AOx, and a PTS2 protein ADAPS were observed as punctate-staining structures at 37°C, indicative of localization in the peroxisome (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>). We reported previously that temperature-sensitive (<italic>ts</italic>) peroxisome assembly is responsible for the milder clinical phenotype of IRD (<xref ref-type="bibr" rid="MCS003483TANC22">Matsumoto et al. 2003b</xref>). To assess the <italic>ts</italic> phenotypic property of Pex26-F51L, cells were cultured at 42°C for 5 d. PTS1 proteins, TH, and catalase were detected in a diffuse staining pattern, suggesting these matrix proteins were not imported to peroxisomes at 42°C (<xref ref-type="fig" rid="MCS003483TANF4">Fig. 4</xref>A). These findings suggest less efficient import of matrix proteins in Pex26-F51L cells at 42°C, whereas endogenous matrix proteins were likely imported normally under normal culture condition at 37°C. To determine whether the mutant forms of Pex26 were expressed in Pex26-F51L fibroblasts, immunoblot analysis was performed with organelle fractions from control and proband fibroblasts, with an anti-Pex26 antibody. A Pex26 band was detected in control cells and Pex26-F51L fibroblasts cultured at 37°C, with a reduced amount in Pex26-F51L cells (<xref ref-type="fig" rid="MCS003483TANF4">Fig. 4</xref>B, lanes 1,3) as in <xref ref-type="fig" rid="MCS003483TANF3">Figure 3</xref>B. In Pex26-F51L fibroblasts cultured at 42°C, the mutated protein was barely detectable (<xref ref-type="fig" rid="MCS003483TANF4">Fig. 4</xref>B, lanes 3,4). We assessed the efficiency of peroxisomal matrix protein import by expressing enhanced GFP (EGFP)-PTS1, PTS2-EGFP, and EGFP-catalase in normal control and proband fibroblasts. The peroxisomal import of newly synthesized EGFP-tagged proteins was significantly decreased in Pex26-F51L fibroblasts as compared to control cells (<xref ref-type="fig" rid="MCS003483TANF5">Fig. 5</xref>). These results show that the mutated Pex26 protein is less effective in the peroxisomal import of matrix proteins.</p><fig id="MCS003483TANF4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Characterization of Pex26-F51L fibroblasts. (<italic>A</italic>) Normal control (N.C.) and patient Pex26-F51L fibroblasts were cultured at 42°C for 5 d and then stained with antibodies to catalase (<italic>a</italic> and <italic>d</italic>), PTS1 (<italic>b</italic> and <italic>e</italic>), and a PTS2 protein (thiolase) (<italic>c</italic> and <italic>f</italic>). Magnification, 630×. (<italic>B</italic>) Organelle fractions each of N.C. and Pex26-F51L fibroblasts were analyzed by SDS-PAGE and immunoblotting with antibodies to Pex26 and PMP70. The solid arrowhead indicates the position of endogenous Pex26.</p></caption><graphic xlink:href="MCS003483Tan_F4"></graphic></fig><fig id="MCS003483TANF5" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Transformation of Pex26-F51L fibroblasts with EGFP-fused PTS1, catalase, and PTS2 proteins. (<italic>Top</italic>) EGFP-PTS1, (<italic>middle</italic>) PTS2-EGFP, and (<italic>bottom</italic>) EGFP-catalase were expressed in normal control and Pex26-F51L fibroblasts, respectively. Cells were cultured for the indicated time at 37°C and observed by EGFP fluorescence. The number of EGFP peroxisome-positive cells was counted in three separate areas. Data represent means ± SEM (<italic>n</italic> = 3). (*) <italic>P</italic> &lt; 0.05, (***) <italic>P</italic> &lt; 0.001; two-sided Welch's <italic>t</italic>-test.</p></caption><graphic xlink:href="MCS003483Tan_F5"></graphic></fig></sec><sec id="s2e"><title>Pex26-F51L Interacts Less with Pex1–Pex6 Complexes</title><p>We previously demonstrated that Pex26 interacts with Pex1–Pex6 complexes in a Pex6-dependent manner (<xref ref-type="bibr" rid="MCS003483TANC38">Tamura et al. 2014</xref>). To determine whether Pex26-F51L affects the interaction with Pex1–Pex6 complexes, we expressed Flag-tagged Pex26-F51L together with Pex1-HA and Pex6-HA in CHO <italic>pex26</italic> ZP167 cells. ZP167 shows no matrix protein import but with detectable membrane remnants (<xref ref-type="bibr" rid="MCS003483TANC12">Ghaedi et al. 1999</xref>; <xref ref-type="bibr" rid="MCS003483TANC22">Matsumoto et al. 2003b</xref>). No transcript for PEX26 was detected (Y Fujiki, unpubl. data). Flag-Pex26-F51L was expressed at a lower level than wild-type Flag-Pex26 (<xref ref-type="fig" rid="MCS003483TANF6">Fig. 6</xref>), consistent with the expression level of endogenous Pex26 in control fibroblasts and mutant protein in Pex26-F51L fibroblasts. Flag-Pex26 and Flag-Pex26-F51L were immunoprecipitated from cell lysates using anti-Flag antibody-conjugated agarose beads and were analyzed by SDS-PAGE and immunoblotting with antibodies to Flag and HA. Pex1-HA and Pex6-HA were detected in the immunoprecipitates of normal Flag-Pex26, consistent with our earlier observation that Pex1-HA and Pex6-HA were co-immunoprecipitated with Flag-Pex26. Pex1-HA and Pex6-HA were only barely discernible in the immunoprecipitates of mutant Flag-Pex26-F51L, indicating that the mutant protein less efficiently recruits the Pex1–Pex6 complexes to peroxisomes (<xref ref-type="fig" rid="MCS003483TANF6">Fig. 6</xref>, right panel).</p><fig id="MCS003483TANF6" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Binding to Pex1 and Pex6 of patient-derived Pex26-F51L. <italic>pex26</italic> CHO ZP167 cells were transfected with plasmids encoding Flag-Pex26 or Flag-Pex26-F51L identified in Pex26-F51L fibroblasts, together with those for Pex6-HA and Pex1-HA. Cells were then cultured at 30°C for 2 d (<xref ref-type="bibr" rid="MCS003483TANC21">Matsumoto et al. 2003a</xref>). Flag-Pex26 and Flag-Pex26-F51L were immunoprecipitated from cell lysates using anti-Flag antibody. Immunoprecipitates (IP) were analyzed by SDS-PAGE and immunoblotting with antibodies to HA and Flag. Input, 5% input. (<italic>Upper</italic> panels) Arrows indicate Pex1-HA and Pex6-HA; (<italic>lower</italic> panels) arrow indicates the migration of Flag-Pex26.</p></caption><graphic xlink:href="MCS003483Tan_F6"></graphic></fig></sec><sec id="s2f"><title>Docosahexaenoic Acid (DHA) Levels Were Decreased in Plasmalogens in Fibroblasts from Patient with <italic>PEX26</italic> Mutations</title><p>Severe defects of peroxisome biogenesis in skin fibroblasts from patients with ZS cause abnormal peroxisomal metabolism, including marked reduction of plasmalogens, accumulation of VLCFA, and reduction of DHA (<xref ref-type="bibr" rid="MCS003483TANC41">Wanders 2004</xref>). To investigate whether the milder defect of peroxisome biogenesis in Pex26-F51L fibroblasts affects peroxisomal metabolisms, phospholipid compositions from control and Pex26-F51L fibroblasts were analyzed by liquid chromatography connected to tandem mass spectrometry (LC-MS/MS). Total amounts of ethanolamine plasmalogens (plasmenylethanolamine, PlsEtn) and VLCFA-containing phosphatidylcholine were not altered in Pex26-F51L cells (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>A,B). Degradation activity by β-oxidation of lignoceric acid (C24:0) in Pex26-F51L fibroblasts was approximately at the same level as that in control cells (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>C), suggesting that peroxisomal fatty acid β-oxidation activity is not affected in Pex26-F51L fibroblasts.</p><fig id="MCS003483TANF7" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>DHA-containing ether phospholipids are reduced in Pex26-F51L fibroblasts. Cellular levels of PlsEtn (<italic>A</italic>) and VLCFA-containing phosphatidylcholine (VLC-PtdCho) (<italic>B</italic>) in control and Pex26-F51L fibroblasts were analyzed by LC-MS/MS. Data represent means ± SEM (<italic>n</italic> = 7). (<italic>C</italic>) Peroxisomal VLCFA β-oxidation activities in control and Pex26-F51L fibroblasts were assessed with <sup>14</sup>C-lignoceric acid (C24:0) as substrate. Data represent means ± SD of three independent experiments. Total amounts (<italic>D</italic>) and compositions (<italic>E</italic>) of DHA-PLs in fibroblasts were detected by LC-MS/MS. Data represented means ± SEM (<italic>n</italic> = 7). (PtdSer) Phosphatidylserine. (*) <italic>P</italic> &lt; 0.05, (***) <italic>P</italic> &lt; 0.001; two-sided Welch's <italic>t</italic>-test.</p></caption><graphic xlink:href="MCS003483Tan_F7"></graphic></fig><p>Synthesis of DHA is initiated at the endoplasmic reticulum and completed by peroxisomal β-oxidation (<xref ref-type="bibr" rid="MCS003483TANC44">Weller et al. 2003</xref>). Defects of peroxisomal biogenesis reduce DHA-containing phospholipids (DHA-PLs) as observed in fibroblasts from patients with ZS (<xref ref-type="bibr" rid="MCS003483TANC1">Abe et al. 2014</xref>). LC-MS/MS analysis revealed that the total amount of DHA-PLs was slightly reduced in Pex26-F51L fibroblasts (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>D), owing to the decrease in DHA-containing ether phospholipids including PlsEtn, which is the most abundant DHA-PL in control fibroblasts, and plasmanylcholine (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>E). On the contrary, DHA-phosphatidylethanolamine was slightly elevated but DHA-phosphatidylcholine was not affected (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>E). Collectively, these results demonstrate that peroxisomal metabolism is functionally intact in Pex26-F51L cells except for the decrease of DHA in ether phospholipids.</p></sec></sec><sec id="s3" sec-type="discussion"><title>DISCUSSION</title><p>Here, we report a novel role for <italic>PEX26</italic> in a cell line from a family with an autosomal recessive, nonsyndromic form of hearing loss. By using ES, we identified a family of four affected individuals with nonsyndromic sensorineural hearing loss, who are homozygous for the novel missense variant, c.153C&gt;A (F51L), in <italic>PEX26</italic>. We have shown with functional cellular assays and biochemical analyses that the F51L mutation confers a previously undescribed mild cellular phenotype of morphologically normal but defective peroxisome biogenesis, including decreased peroxisomal protein import.</p><p>We analyzed patient-derived Pex26-F51L fibroblasts by immunocytochemistry and the “temperature sensitivity” assay to determine the effect of the F51L mutation on Pex26 protein function. Earlier studies on patient-derived fibroblasts have demonstrated the association between <italic>PEX26</italic> mutations found in patients with a clinically milder phenotype and the <italic>ts</italic> cellular phenotype that results from these mutations (<xref ref-type="bibr" rid="MCS003483TANC34">Steinberg et al. 2006</xref>). In general, fibroblasts from patients with mild ZSD disease have a <italic>ts</italic> phenotype, whereas fibroblasts with <italic>PEX26</italic> mutations causing the severe ZS clinical phenotype are not <italic>ts</italic>. Previous experiments on cell lines with pathogenic missense variants in <italic>PEX</italic> genes have shown that <italic>PEX</italic>-deficient fibroblasts incubated at 37°C produce a more severe cellular phenotype based on PTS1 and PTS2 import than when cultured at 30°C (<xref ref-type="bibr" rid="MCS003483TANC7">Fujiki 2003</xref>; <xref ref-type="bibr" rid="MCS003483TANC10">Fujiki et al. 2014</xref>). The lower temperature is presumed to allow the mutated protein to attain a more relaxed conformation, which enhances its function, whereas culture conditions at higher temperatures exacerbates the defect in cells yielding a milder import phenotype (<xref ref-type="bibr" rid="MCS003483TANC34">Steinberg et al. 2006</xref>).</p><p>We thus characterized the effect of the F51L mutation on Pex26 function by incubating Pex26-F51L cells at 30°C, 37°C, and 42°C and quantifying peroxisomal import of matrix proteins at each temperature. On initial examination of cells cultured at 37°C, peroxisomal import of matrix proteins, including PTS1 and PTS2, and expression of PMPs by Pex26-F51L cells appeared normal and showed no difference from control fibroblasts cultured at 37°C (<xref ref-type="fig" rid="MCS003483TANF2">Fig. 2</xref>). However, at 42°C, Pex26-F51L cells exhibited significantly delayed and decreased peroxisomal assembly and matrix protein import as compared to wild-type control fibroblasts (<xref ref-type="fig" rid="MCS003483TANF4">Fig. 4</xref>A), indicating destabilization of Pex26 protein activity. Interestingly, we noted that although catalase levels were significantly elevated in Pex26-F51L cells (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>A), the total amount of Pex26 protein was reduced to ∼30% as compared to control fibroblasts (<xref ref-type="fig" rid="MCS003483TANF3">Fig. 3</xref>B). This indicates that the mutated protein product in Pex26-F51L cells is unstable. Our results collectively show the F51L mutation causes a very mild cellular phenotype representing morphologically normal but biochemically detectable defects in peroxisome biogenesis, including decreased peroxisomal protein import.</p><p>We further investigated the effect of the F51L mutation on peroxisomal metabolism by measuring peroxisomal fatty acid β-oxidation activity, plasmalogen biosynthesis, and DHA content. Patients with ZSDs show severe defects in peroxisome biogenesis, which results in abnormal peroxisomal metabolism, including marked reduction of PlsEtn, accumulation of VLCFA, and reduction of DHA (<xref ref-type="bibr" rid="MCS003483TANC42">Wanders and Waterham 2006</xref>; <xref ref-type="bibr" rid="MCS003483TANC1">Abe et al. 2014</xref>; <xref ref-type="bibr" rid="MCS003483TANC10">Fujiki et al. 2014</xref>). The reduction of plasmalogens gives rise to the up-regulation of Far1 proteins, the rate-limiting enzyme of plasmalogen biosynthesis, in a manner dependent on cellular plasmalogen levels (<xref ref-type="bibr" rid="MCS003483TANC16">Honsho et al. 2010</xref>). In fibroblasts from patients who carry defects in peroxisomal fatty acid β-oxidation, DHA contents are markedly reduced and peroxisomes are much less abundant than in wild-type cells. We previously found that DHA is a crucial signal for the morphogenesis of peroxisomes, and, moreover, treatment of β-oxidation-deficient fibroblasts with DHA induces peroxisomal proliferation (<xref ref-type="bibr" rid="MCS003483TANC19">Itoyama et al. 2012</xref>). DHA treatment may therefore provide a therapeutic approach to stimulate peroxisome formation and ostensibly rescue peroxisomal β-oxidation activity in patients with PBD.</p><p>We therefore examined Far1 and DHA levels in Pex26-F51L cells and demonstrated that the F51L mutation results in normal level of total plasmalogens and peroxisomal β-oxidation activity (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>A,C). But, of note, the levels of DHA in ether phospholipids (DHA-containing plasmalogens) were reduced (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>D), whereas DHA-phosphatidylethanolamine levels were slightly elevated (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>E). In control fibroblasts, components identified in DHA-PLs suggest DHA is preferentially incorporated into plasmalogens (<xref ref-type="fig" rid="MCS003483TANF7">Fig. 7</xref>E), although its underlying mechanism is not well understood. We have shown previously that in fibroblasts deficient in peroxisomal fatty acid β-oxidation, all classes of DHA-PLs are reduced (<xref ref-type="bibr" rid="MCS003483TANC19">Itoyama et al. 2012</xref>). It is therefore plausible that the retarded peroxisomal import of matrix proteins exhibited by Pex26-F51L cells affects the biosynthesis of DHA-containing plasmalogens. The abnormal ratio of constituents in the DHA-ether lipids may also suggest the defect underlying the phenotype of hearing loss, whereas the causal mechanism is unclear.</p><p>Sensorineural hearing loss results from malfunction of inner ear structures, including the cochlea and auditory nerve. It would thus be necessary to study <italic>PEX26</italic> expression and function in the sound sensing cells, such as the cochlear inner hair cells, from patient-derived cell lines or animal models of deafness. Deletion of the DNB40 locus on 22q11.21-12.1, which includes the <italic>PEX26</italic> gene, has been previously associated with autosomal recessive sensorineural hearing loss (<xref ref-type="bibr" rid="MCS003483TANC23">Delmaghani et al. 2003</xref>). Three otherwise healthy siblings with sensorineural hearing loss from a consanguineous Iranian family were identified to be homozygous for a ∼9-Mb deletion encompassing the 22q11.21-12.1 chromosome region, which contains more than 80 genes. Several of the genes in this region for which nonsyndromic and syndromic hearing impairment have been associated, including <italic>TBX1</italic>, <italic>DGCR6</italic>, and <italic>CRYBB1</italic>, were examined in additional families with a recessive form of hearing loss, but no mutations were detected in the coding regions of these genes (<xref ref-type="bibr" rid="MCS003483TANC23">Delmaghani et al. 2003</xref>). A recent study by the same team of researchers reported decreased levels of peroxisomal biogenesis in the cochlear cells of Persian families with sensorineural hearing loss who harbor a specific mutation in the <italic>PJVK</italic> gene (<xref ref-type="bibr" rid="MCS003483TANC4">Delmaghani et al. 2015</xref>). The <italic>PJVK</italic> gene encodes the gasdermin protein, pejvakin (PJVK), which is required for auditory neuronal function in vertebrates, and mutations in <italic>PJVK</italic> are known to cause autosomal recessive deafness 59 (OMIM#610220). It is hypothesized that <italic>PJVK</italic> plays an essential role in regulating peroxisomal dynamics in mechanosensory hair cells of the inner ear (<xref ref-type="bibr" rid="MCS003483TANC4">Delmaghani et al. 2015</xref>). It is thus possible that the F51L mutation in <italic>PEX26</italic> from our patients’ family may also predominantly affect the cells of the inner ear responsible for sensorineural hearing.</p><p>In summary, we have identified and characterized a novel variant in <italic>PEX26</italic> from a family with nonsyndromic sensorineural hearing loss. The F51L missense variant in <italic>PEX26</italic> causes a mild defect in peroxisome biogenesis, including decreased peroxisomal protein import and reduced levels of DHA-PLs. It remains to be determined how the F51L variant affecting the function and expression of <italic>PEX26</italic> causes hearing loss. Testing of individuals with sensorineural hearing loss in AJ communities may help to identify more individuals with Pex26-associated hearing loss and will allow us to elucidate the underlying molecular defect linking the F51L cellular phenotype to hearing loss in patients.</p></sec><sec id="s4" sec-type="methods"><title>METHODS</title><p>Studies were approved by the Institutional Review Board of Columbia University.</p><sec id="s4a"><title>Exome Sequencing</title><p>Genomic DNA was extracted from whole blood from the affected children and their parents. Exome sequencing at GeneDx was performed on exon targets captured using the Agilent SureSelect Human All Exon V4 (50 Mb) or the Clinical Research Exome kit (Agilent Technologies) according to the manufacturer's instructions. Libraries were sequenced using the Illumina HiSeq 2000 or 2500 sequencing system with 100-bp paired-end reads (Illumina). Whole-exome sequence data for all sequenced family members was analyzed using GeneDx's XomeAnalyzer (a variant annotation, filtering, and viewing interface for exome sequencing data) as described previously (<xref ref-type="bibr" rid="MCS003483TANC39">Tanaka et al. 2017</xref>). The identified sequence variant of interest was confirmed in the proband, affected siblings, and both parents by conventional di-deoxy DNA sequence analysis using an ABI3730 (Life Technologies).</p></sec><sec id="s4b"><title>RT-PCR</title><p>Poly(A)<sup>+</sup> RNA was obtained from fibroblasts from a proband with sensorineural hearing loss by a QuickPrep mRNA purification kit (Amersham Biosciences). RT-PCR of <italic>PEX26</italic> was performed with a pair of forward primer 1F (5′-AAGAGCGATTCTTCGACC-3′ at amino acid residues 4–21 and reverse primer 1R (5′-GTCACGGATGCGGAGCTG-3′ at 898–915 (<xref ref-type="bibr" rid="MCS003483TANC21">Matsumoto et al. 2003a</xref>). PCR products were directly sequenced.</p></sec><sec id="s4c"><title>Patient-Derived Cell Line</title><p>Punch skin biopsy was performed on the proband to create a cell line for functional analysis.</p></sec><sec id="s4d"><title>Cell Culture</title><p>Control fibroblasts and Pex26-F51L fibroblasts were maintained in DMEM (Invitrogen), and a <italic>PEX26</italic>-deficient CHO cell mutant ZP167 (Matsumoto et al. 2003a) was maintained in Ham's F-12 medium (Invitrogen); both media were supplemented with 10% FBS under conditions of 5% CO<sub>2</sub>, 95% air at 37°C. For analysis of <italic>ts</italic> phenotype, fibroblasts were cultured for 5 d at 42°C.</p></sec><sec id="s4e"><title>Antibodies</title><p>Rabbit antisera to catalase (<xref ref-type="bibr" rid="MCS003483TANC40">Tsukamoto et al. 1990</xref>), PTS1 (<xref ref-type="bibr" rid="MCS003483TANC30">Otera et al. 1998</xref>), AOx (<xref ref-type="bibr" rid="MCS003483TANC40">Tsukamoto et al. 1990</xref>), ADAPS (<xref ref-type="bibr" rid="MCS003483TANC15">Honsho et al. 2008</xref>), TH (<xref ref-type="bibr" rid="MCS003483TANC40">Tsukamoto et al. 1990</xref>), SCPx (<xref ref-type="bibr" rid="MCS003483TANC31">Otera et al. 2001</xref>), DHAPAT (<xref ref-type="bibr" rid="MCS003483TANC17">Honsho et al. 2017</xref>), Far1 (<xref ref-type="bibr" rid="MCS003483TANC16">Honsho et al. 2010</xref>), PsLon (<xref ref-type="bibr" rid="MCS003483TANC27">Okumoto et al. 2011</xref>), Tysnd1 (<xref ref-type="bibr" rid="MCS003483TANC27">Okumoto et al. 2011</xref>), PMP70 (<xref ref-type="bibr" rid="MCS003483TANC40">Tsukamoto et al. 1990</xref>), Pex14 (<xref ref-type="bibr" rid="MCS003483TANC14">Harano et al. 1999</xref>), Pex13 (<xref ref-type="bibr" rid="MCS003483TANC25">Mukai and Fujiki 2006</xref>), and Pex26 (<xref ref-type="bibr" rid="MCS003483TANC21">Matsumoto et al. 2003a</xref>) were used. Mouse monoclonal antibodies to the Flag epitope (M2; Sigma-Aldrich), influenza virus hemagglutinin (HA) (16B12; Covance), P450 reductase (F-10; Santa Cruz), and Tom20 (F-10; Santa Cruz) and goat antiserum to lactate dehydrogenase (Rockland) were purchased.</p></sec><sec id="s4f"><title>Extraction of Phospholipid from Fibroblasts</title><p>Fibroblasts plated in the six-well plate were dissociated by trypsin treatment and then suspended in PBS. Protein concentration of the cell suspension was determined by bicinchonic acid methods using a Pierce BCA protein assay kit (Thermo Fisher Scientific). Total lipids were extracted from 50 µg of total cellular proteins by the Bligh and Dyer method (<xref ref-type="bibr" rid="MCS003483TANC3">Bligh and Dyer 1959</xref>). Cells were suspended in methanol/chloroform/water at 2:1:0.8 (v/v/v) and then 50 pmol of 1,2-didodecanoyl-<italic>sn</italic>-glycero-3-phosphocholine (DDPC, Avanti Polar Lipids) and 1,2-didodecanoyl-<italic>sn</italic>-glycero-3-phosphoethanolamine (DDPE, Avanti Polar Lipids) were added as internal standards. After incubation for 5 min at room temperature, 1 mL each of water and chloroform was added and the samples were then centrifuged at 2000 rpm for 5 min in Himac CF-16RX (Hitachi Koki) to collect the lower organic phase. To re-extract lipids from the water phase, 1 mL chloroform was added. Combined organic phase was evaporated under a nitrogen stream and the extracted lipids were dissolved in methanol.</p></sec><sec id="s4g"><title>Liquid Chromatography Coupled with Tandem Mass Spectrometry (LC-MS/MS)</title><p>LC-MS/MS was performed as described (<xref ref-type="bibr" rid="MCS003483TANC1">Abe et al. 2014</xref>) using a 4000 Q-TRAP quadrupole linear ion trap hybrid mass spectrometer (AB Sciex) with an ACQUITY UPLC System (Waters). The data were analyzed and quantified using Analyst software version 1.42 (AB Sciex).</p></sec><sec id="s4h"><title>Measurement of Fatty Acid β-Oxidation Activity</title><p>Fatty acid β-oxidation activity was determined as described (<xref ref-type="bibr" rid="MCS003483TANC36">Suzuki et al. 1991</xref>). Cells grown in six-well plates were preincubated for 1 h at 37°C in serum-free DMEM. After the medium was changed to fresh serum-free DMEM, 2 nmol of <sup>14</sup>C-C24:0 (American Radiolabeled Chemicals) in 0.1 M Tris-HCl, pH 8.0, containing 10 mM α-cyclodextrin was added to the culture medium, and cells were further incubated for 2 h at 37°C. The radioactivity of acid-soluble metabolites was measured using an AccuFLEX LSC-8000 (Hitachi). Fatty acid β-oxidation activity was calculated as nmol/h/mg of protein.</p></sec><sec id="s4i"><title>Other Methods</title><p>Immunoblotting and immunofluorescence microscopy were performed as described (<xref ref-type="bibr" rid="MCS003483TANC18">Hosoi et al. 2017</xref>).</p></sec></sec><sec id="s5"><title>ADDITIONAL INFORMATION</title><sec id="s5a" sec-type="data-availability"><title>Data Deposition and Access</title><p>Whole-exome sequencing data are not publicly available because patient consent could not be obtained. The PEX26 variant found in this study has been deposited in ClinVar (<uri xlink:href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.ncbi.nlm.nih.gov_clinvar_&amp;d=DwICJg&amp;c=mkpgQs82XaCKIwNV8b32dmVOmERqJe4bBOtF0CetP9Y&amp;r=OVgK9N-fohjgKXCkC0sSYQ&amp;m=0R7rL3r5MeZgk1YPetn3FofhMnnojEQrVN7TTJtyfcg&amp;s=iHLSL53bxvs_xveEcnjiKhAgv-wrsDoprnldboINBpc&amp;e=">https://urldefense.proofpoint.com/v2/url?u=http-3A__www.ncbi.nlm.nih.gov_clinvar_&amp;d=DwICJg &amp;c=mkpgQs82XaCKIwNV8b32dmVOmERqJe4bBOtF0CetP9Y&amp;r=OVgK9N-fohjgKXCkC0sSYQ&amp;m=0R7rL3r5MeZgk1YPetn3FofhMnnojEQrVN7TTJtyfcg&amp;s=iHLSL53bxvs_xveEcnjiK hAgv-wrsDoprnldboINBpc&amp;e=</uri>) under accession number SCV000804559.</p></sec><sec id="s5b"><title>Ethics Statement</title><p>The study was approved by the Institutional Review Board of Columbia University. Written informed consent was obtained from the probands or proband's siblings and parents for publication.</p></sec><sec id="s5c"><title>Acknowledgments</title><p>We thank M. Ishii for preparing figures and the other members of Fujiki laboratory for discussions. This work was supported in part by Grants-in-Aid for Scientific Research JP26116007, JP15K21743 and JP17H03675 (to Y.F.) and grants from the Takeda Science Foundation, the Naito Foundation, the Japan Foundation for Applied Enzymology, and Novartis Foundation (Japan) for the Promotion of Science (to Y.F.) and from the JPB Foundation and Simons Foundation (to W.K.C.).</p></sec><sec id="s5d"><title>Author Contributions</title><p>A.J.T., K.O., S.T., Y.A., Y.F., Y.H., and W.K.C. conceived and designed the study; K.O., S.T., L.D., and J.E. performed cell culture, morphological, and biochemical analyses; Y.A. performed lipidomic analysis; K.O., A.J.T., L.D., W.K.C., S.T., Y.A., and Y.F. interpreted data and wrote the manuscript.</p></sec><sec id="s5e"><title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></sec></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="PMC_1">
<caption>
<title>Supplemental Material</title>
</caption>
<media mime-subtype="html" mimetype="text" xlink:href="supp_5_1_a003483__index.html"></media>
<media mime-subtype="msword" mimetype="application" xlink:href="supp_mcs.a003483_Supplemental_Table_S1.docx" xlink:role="associated-file"></media>
<media mime-subtype="msword" mimetype="application" xlink:href="supp_mcs.a003483_Supplemental_Table_S2.docx" xlink:role="associated-file"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>[Supplemental material is available for this article.]</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="MCS003483TANC1">
<mixed-citation publication-type="journal"><string-name><surname>Abe</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Honsho</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nakanishi</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Taguchi</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2014</year>
<article-title>Very-long-chain polyunsaturated fatty acids accumulate in phosphatidylcholine of fibroblasts from patients with Zellweger syndrome and acyl-CoA oxidase 1 deficiency</article-title>. <source/>Biochim Biophys Acta
<volume>1841</volume>: <fpage>610</fpage>–<lpage>619</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2014.01.001</pub-id><pub-id pub-id-type="pmid">24418004</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC2">
<mixed-citation publication-type="journal"><string-name><surname>Barøy</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Koster</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Strømme</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ebberink</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Misceo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ferdinandusse</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Holmgren</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hughes</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Merckoll</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Westvik</surname>
<given-names>J</given-names></string-name>, <etal></etal>
<year>2015</year>
<article-title>A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform</article-title>. <source/>Hum Mol Genet
<volume>24</volume>: <fpage>5845</fpage>–<lpage>5854</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddv305</pub-id><pub-id pub-id-type="pmid">26220973</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC3">
<mixed-citation publication-type="journal"><string-name><surname>Bligh</surname>
<given-names>EG</given-names></string-name>, <string-name><surname>Dyer</surname>
<given-names>WJ</given-names></string-name>. <year>1959</year>
<article-title>A rapid method of total lipid extraction and purification</article-title>. <source/>Can J Biochem Physiol
<volume>37</volume>: <fpage>911</fpage>–<lpage>917</lpage>. <pub-id pub-id-type="doi">10.1139/y59-099</pub-id><pub-id pub-id-type="pmid">13671378</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC23">
<mixed-citation publication-type="journal"><string-name><surname>Delmaghani</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Aghaie</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Compain-Nouaille</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ataie</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lemainque</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zeinali</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lathrop</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Weil</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Petit</surname>
<given-names>C</given-names></string-name>. <year>2013</year>
<article-title>DFNB40, a recessive form of sensorineural hearing loss, maps to chromosome 22q11.21-12.1</article-title>. <source/>Eur J Hum Genet
<volume>11</volume>: <fpage>816</fpage>–<lpage>818</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5201045</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC4">
<mixed-citation publication-type="journal"><string-name><surname>Delmaghani</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Defourny</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Aghaie</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Beurg</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dulon</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Thelen</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Perfettini</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Zelles</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Aller</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Meyer</surname>
<given-names>A</given-names></string-name>, <etal></etal>
<year>2015</year>
<article-title>Hypervulnerability to sound exposure through impaired adaptive proliferation of peroxisomes</article-title>. <source/>Cell
<volume>163</volume>: <fpage>894</fpage>–<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.10.023</pub-id><pub-id pub-id-type="pmid">26544938</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC5">
<mixed-citation publication-type="journal"><string-name><surname>de Vet</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Ijlst</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Oostheim</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Wanders</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>van den Bosch</surname>
<given-names>H</given-names></string-name>. <year>1998</year>
<article-title>Alkyl-dihydroxyacetonephosphate synthase. Fate in peroxisome biogenesis disorders and identification of the point mutation underlying a single enzyme deficiency</article-title>. <source/>J Biol Chem
<volume>273</volume>: <fpage>10296</fpage>–<lpage>10301</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.273.17.10296</pub-id><pub-id pub-id-type="pmid">9553082</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC6">
<mixed-citation publication-type="journal"><string-name><surname>Ebberink</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Mooijer</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Gootjes</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Koster</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wanders</surname>
<given-names>RJA</given-names></string-name>, <string-name><surname>Waterham</surname>
<given-names>HR</given-names></string-name>. <year>2011</year>
<article-title>Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder</article-title>. <source/>Hum Mutat
<volume>32</volume>: <fpage>59</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21388</pub-id><pub-id pub-id-type="pmid">21031596</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC7">
<mixed-citation publication-type="book"><string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2003</year>
<article-title>Peroxisome biogenesis disorders</article-title>. In <source/>Encyclopedia of the human genome (ed. <string-name><surname>Cooper</surname>
<given-names>DN</given-names></string-name>), Vol. <volume>4</volume>, pp. <fpage>541</fpage>–<lpage>547</lpage>. <publisher-name>Nature Publishing Group</publisher-name>, <publisher-loc>London</publisher-loc>.</mixed-citation>
</ref>
<ref id="MCS003483TANC8">
<mixed-citation publication-type="journal"><string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2016</year>
<article-title>Peroxisome biogenesis and human peroxisome-deficiency disorders</article-title>. <source/>Proc Jpn Acad Ser B Phys Biol Sci
<volume>92</volume>: <fpage>463</fpage>–<lpage>477</lpage>. <pub-id pub-id-type="doi">10.2183/pjab.92.463</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC9">
<mixed-citation publication-type="journal"><string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Okumoto</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kinoshita</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ghaedi</surname>
<given-names>K</given-names></string-name>. <year>2006</year>
<article-title>Lessons from peroxisome-deficient Chinese hamster ovary (CHO) cell mutants</article-title>. <source/>Biochim Biophys Acta
<volume>1763</volume>: <fpage>1374</fpage>–<lpage>1381</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.09.012</pub-id><pub-id pub-id-type="pmid">17045664</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC10">
<mixed-citation publication-type="journal"><string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Okumoto</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mukai</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Honsho</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tamura</surname>
<given-names>S</given-names></string-name>. <year>2014</year>
<article-title>Peroxisome biogenesis in mammalian cells</article-title>. <source/>Front Physiol
<volume>5</volume>: <fpage>307</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2014.00307</pub-id>.<pub-id pub-id-type="pmid">25177298</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC11">
<mixed-citation publication-type="journal"><string-name><surname>Furuki</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tamura</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Matsumoto</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Miyata</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>HW</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2006</year>
<article-title>Mutations in the peroxin Pex26p responsible for peroxisome biogenesis disorders of complementation group 8 impair its stability, peroxisomal localization, and interaction with the Pex1p-Pex6p complex</article-title>. <source/>J Biol Chem
<volume>281</volume>: <fpage>1317</fpage>–<lpage>1323</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M510044200</pub-id><pub-id pub-id-type="pmid">16257970</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC12">
<mixed-citation publication-type="journal"><string-name><surname>Ghaedi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Itagaki</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Toyama</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Tamura</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Matsumura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kawai</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shimozawa</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Suzuki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>1999</year>
<article-title>Newly identified Chinese hamster ovary cell mutants defective in peroxisome assembly represent complementation group A of human peroxisome biogenesis disorders and one novel group in mammals</article-title>. <source/>Exp Cell Res
<volume>248</volume>: <fpage>482</fpage>–<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1006/excr.1999.4412</pub-id><pub-id pub-id-type="pmid">10222139</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC13">
<mixed-citation publication-type="journal"><string-name><surname>Gould</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Valle</surname>
<given-names>D</given-names></string-name>. <year>2000</year>
<article-title>Peroxisome biogenesis disorders: genetics and cell biology</article-title>. <source/>Trends Genet
<volume>16</volume>: <fpage>340</fpage>–<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1016/S0168-9525(00)02056-4</pub-id><pub-id pub-id-type="pmid">10904262</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC14">
<mixed-citation publication-type="journal"><string-name><surname>Harano</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Shimizu</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Otera</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>1999</year>
<article-title>Transmembrane topology of the peroxin, Pex2p, an essential component for the peroxisome assembly</article-title>. <source/>J Biochem
<volume>125</volume>: <fpage>1168</fpage>–<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a022400</pub-id><pub-id pub-id-type="pmid">10348921</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC15">
<mixed-citation publication-type="journal"><string-name><surname>Honsho</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yagita</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kinoshita</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2008</year>
<article-title>Isolation and characterization of mutant animal cell line defective in alkyl-dihydroxyacetonephosphate synthase: localization and transport of plasmalogens to post-Golgi compartments</article-title>. <source/>Biochim Biophys Acta
<volume>1783</volume>: <fpage>1857</fpage>–<lpage>1865</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.05.018</pub-id><pub-id pub-id-type="pmid">18571506</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC16">
<mixed-citation publication-type="journal"><string-name><surname>Honsho</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Asaoku</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2010</year>
<article-title>Posttranslational regulation of fatty acyl-CoA reductase 1, Far1, controls ether glycerophospholipid synthesis</article-title>. <source/>J Biol Chem
<volume>285</volume>: <fpage>8537</fpage>–<lpage>8542</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.083311</pub-id><pub-id pub-id-type="pmid">20071337</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC17">
<mixed-citation publication-type="journal"><string-name><surname>Honsho</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Abe</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2017</year>
<article-title>Plasmalogen biosynthesis is spatiotemporally regulated by sensing plasmalogens in the inner leaflet of plasma membranes</article-title>. <source/>Sci Rep
<volume>7</volume>: <fpage>43936</fpage>
<pub-id pub-id-type="doi">10.1038/srep43936</pub-id>.<pub-id pub-id-type="pmid">28272479</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC18">
<mixed-citation publication-type="journal"><string-name><surname>Hosoi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Miyata</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Mukai</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Furuki</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Okumoto</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>EH</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2017</year>
<article-title>The VDAC2-BAK axis regulates peroxisomal membrane permeability</article-title>. <source/>J Cell Biol
<volume>216</volume>: <fpage>709</fpage>–<lpage>721</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201605002</pub-id><pub-id pub-id-type="pmid">28174205</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC19">
<mixed-citation publication-type="journal"><string-name><surname>Itoyama</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Honsho</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Abe</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yoshida</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2012</year>
<article-title>Docosahexaenoic acid mediates peroxisomal elongation, a prerequisite for peroxisome division</article-title>. <source/>J Cell Sci
<volume>125</volume>: <fpage>589</fpage>–<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.087452</pub-id><pub-id pub-id-type="pmid">22389399</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC20">
<mixed-citation publication-type="journal"><string-name><surname>Kurochkin</surname>
<given-names>IV</given-names></string-name>, <string-name><surname>Mizuno</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Konagaya</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sakaki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Schönbach</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Okazaki</surname>
<given-names>Y</given-names></string-name>. <year>2007</year>
<article-title>Novel peroxisomal protease Tysnd1 processes PTS1- and PTS2-containing enzymes involved in β-oxidation of fatty acids</article-title>. <source/>EMBO J
<volume>26</volume>: <fpage>835</fpage>–<lpage>845</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7601525</pub-id><pub-id pub-id-type="pmid">17255948</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC21">
<mixed-citation publication-type="journal"><string-name><surname>Matsumoto</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Tamura</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2003a</year>
<article-title>The pathogenic peroxin Pex26p recruits the Pex1p-Pex6p AAA ATPase complexes to peroxisomes</article-title>. <source/>Nat Cell Biol
<volume>5</volume>: <fpage>454</fpage>–<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1038/ncb982</pub-id><pub-id pub-id-type="pmid">12717447</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC22">
<mixed-citation publication-type="journal"><string-name><surname>Matsumoto</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Tamura</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Furuki</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Miyata</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shimozawa</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>HW</given-names></string-name>, <string-name><surname>Suzuki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kondo</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2003b</year>
<article-title>Mutations in novel peroxin gene <italic>PEX26</italic> that cause peroxisome-biogenesis disorders of complementation group 8 provide a genotype-phenotype correlation</article-title>. <source/>Am J Hum Genet
<volume>73</volume>: <fpage>233</fpage>–<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1086/377004</pub-id><pub-id pub-id-type="pmid">12851857</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC24">
<mixed-citation publication-type="journal"><string-name><surname>Miyazawa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Osumi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hashimoto</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ohno</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Miura</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>1989</year>
<article-title>Peroxisome targeting signal of rat liver acyl-coenzyme A oxidase resides at the carboxy terminus</article-title>. <source/>Mol Cell Biol
<volume>9</volume>: <fpage>83</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.9.1.83</pub-id><pub-id pub-id-type="pmid">2927399</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC25">
<mixed-citation publication-type="journal"><string-name><surname>Mukai</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2006</year>
<article-title>Molecular mechanisms of import of peroxisome-targeting signal type 2 (PTS2) proteins by PTS2 receptor Pex7p and PTS1 receptor Pex5pL</article-title>. <source/>J Biol Chem
<volume>281</volume>: <fpage>37311</fpage>–<lpage>37320</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M607178200</pub-id><pub-id pub-id-type="pmid">17040904</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC26">
<mixed-citation publication-type="journal"><string-name><surname>Neuhaus</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Eisenberger</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Decker</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Nagl</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Blank</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pfister</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kennerknecht</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Mueller-Hofstede</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Issa</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Heller</surname>
<given-names>R</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>Next-generation sequencing reveals the mutational landscape of clinically diagnosed Usher syndrome: copy number variations, phenocopies, a predominant target for translational read-through, and <italic>PEX26</italic> mutated in Heimler syndrome</article-title>. <source/>Mol Genet Genom Med
<volume>5</volume>: <fpage>531</fpage>–<lpage>552</lpage>. <pub-id pub-id-type="doi">10.1002/mgg3.312</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC27">
<mixed-citation publication-type="journal"><string-name><surname>Okumoto</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kametani</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2011</year>
<article-title>Two proteases, trypsin domain-containing 1 (Tysnd1) and peroxisomal Lon protease (PsLon), cooperatively regulate fatty-acid β-oxidation in peroxisomal matrix</article-title>. <source/>J Biol Chem
<volume>286</volume>: <fpage>44367</fpage>–<lpage>44379</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.285197</pub-id><pub-id pub-id-type="pmid">22002062</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC29">
<mixed-citation publication-type="journal"><string-name><surname>Osumi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Tsukamoto</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hata</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yokota</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Miura</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hijikata</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Miyazawa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hashimoto</surname>
<given-names>T</given-names></string-name>. <year>1991</year>
<article-title>Amino-terminal presequence of the precursor of peroxisomal 3-ketoacyl-CoA thiolase is a cleavable signal peptide for peroxisomal targeting</article-title>. <source/>Biochem Biophys Res Commun
<volume>181</volume>: <fpage>947</fpage>–<lpage>954</lpage>. <pub-id pub-id-type="doi">10.1016/0006-291X(91)92028-I</pub-id><pub-id pub-id-type="pmid">1764107</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC30">
<mixed-citation publication-type="journal"><string-name><surname>Otera</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Okumoto</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Tateishi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ikoma</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Matsuda</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Nishimura</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tsukamoto</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Osumi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ohashi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Higuchi</surname>
<given-names>O</given-names></string-name>, <etal></etal>
<year>1998</year>
<article-title>Peroxisome targeting signal type 1 (PTS1) receptor is involved in import of both PTS1 and PTS2: studies with <italic>PEX5</italic>-defective CHO cell mutants</article-title>. <source/>Mol Cell Biol
<volume>18</volume>: <fpage>388</fpage>–<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.18.1.388</pub-id><pub-id pub-id-type="pmid">9418886</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC31">
<mixed-citation publication-type="journal"><string-name><surname>Otera</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Nishimura</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Setoguchi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2001</year>
<article-title>Biogenesis of nonspecific lipid transfer protein and sterol carrier protein x: studies using peroxisome assembly-defective <italic>pex</italic> cell mutants</article-title>. <source/>J Biol Chem
<volume>276</volume>: <fpage>2858</fpage>–<lpage>2864</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M007730200</pub-id><pub-id pub-id-type="pmid">11042217</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC32">
<mixed-citation publication-type="journal"><string-name><surname>Shimozawa</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Tsukamoto</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Suzuki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Orii</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>1992</year>
<article-title>Animal cell mutants represent two complementation groups of peroxisome-defective Zellweger syndrome</article-title>. <source/>J Clin Invest
<volume>90</volume>: <fpage>1864</fpage>–<lpage>1870</lpage>. <pub-id pub-id-type="doi">10.1172/JCI116063</pub-id><pub-id pub-id-type="pmid">1430210</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC33">
<mixed-citation publication-type="journal"><string-name><surname>Steinberg</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Cutting</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Braverman</surname>
<given-names>N</given-names></string-name>. <year>2004</year>
<article-title>The PEX gene screen: molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum</article-title>. <source/>Mol Genet Metab
<volume>83</volume>: <fpage>252</fpage>–<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2004.08.008</pub-id><pub-id pub-id-type="pmid">15542397</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC34">
<mixed-citation publication-type="journal"><string-name><surname>Steinberg</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Dodt</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Raymond</surname>
<given-names>GV</given-names></string-name>, <string-name><surname>Braverman</surname>
<given-names>NE</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Moser</surname>
<given-names>HW</given-names></string-name>. <year>2006</year>
<article-title>Peroxisome biogenesis disorders</article-title>. <source/>Biochim Biophys Acta
<volume>1763</volume>: <fpage>1733</fpage>–<lpage>1748</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.09.010</pub-id><pub-id pub-id-type="pmid">17055079</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC35">
<mixed-citation publication-type="journal"><string-name><surname>Stowe</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Agarwal</surname>
<given-names>S</given-names></string-name>. <year>2017</year>
<article-title>Novel <italic>PEX26</italic> mutation causing Zellweger syndrome presenting as feeding intolerance and hypotonia</article-title>. <source/>Pediat Neurol
<volume>75</volume>: <fpage>96</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2017.06.012</pub-id><pub-id pub-id-type="pmid">28823628</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC36">
<mixed-citation publication-type="journal"><string-name><surname>Suzuki</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shimozawa</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Yajima</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yamaguchi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Orii</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hashimoto</surname>
<given-names>T</given-names></string-name>. <year>1991</year>
<article-title>Effects of sodium 2-[5-(4-chlorophenyl)pentyl]-oxirane-2-carboxylate (POCA) on fatty acid oxidation in fibroblasts from patients with peroxisomal diseases</article-title>. <source/>Biochem Pharmacol
<volume>41</volume>: <fpage>453</fpage>–<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(91)90544-F</pub-id><pub-id pub-id-type="pmid">1994902</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC37">
<mixed-citation publication-type="journal"><string-name><surname>Swinkels</surname>
<given-names>BW</given-names></string-name>, <string-name><surname>Gould</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Bodnar</surname>
<given-names>AG</given-names></string-name>, <string-name><surname>Rachubinski</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Subramani</surname>
<given-names>S</given-names></string-name>. <year>1991</year>
<article-title>A novel, cleavable peroxisomal targeting signal at the amino-terminus of the rat 3-ketoacyl-CoA thiolase</article-title>. <source/>EMBO J
<volume>10</volume>: <fpage>3255</fpage>–<lpage>3262</lpage>. <pub-id pub-id-type="doi">10.1002/j.1460-2075.1991.tb04889.x</pub-id><pub-id pub-id-type="pmid">1680677</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC38">
<mixed-citation publication-type="journal"><string-name><surname>Tamura</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Matsumoto</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Takeba</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>2014</year>
<article-title>AAA peroxins and their recruiter Pex26p modulate the interactions of peroxins involved in peroxisomal protein import</article-title>. <source/>J Biol Chem
<volume>289</volume>: <fpage>24336</fpage>–<lpage>24346</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.588038</pub-id><pub-id pub-id-type="pmid">25016021</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC39">
<mixed-citation publication-type="journal"><string-name><surname>Tanaka</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Willaert</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Retterer</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Zarate</surname>
<given-names>YA</given-names></string-name>, <string-name><surname>Bosanko</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Stefans</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Oishi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Williamson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>GN</given-names></string-name>, <etal></etal>
<year>2017</year>
<article-title>De novo variants in EBF3 are associated with hypotonia, developmental delay, intellectual disability, and autism</article-title>. <source/>Cold Spring Harb Mol Case Stud
<volume>3</volume>: <fpage>a002097</fpage>
<pub-id pub-id-type="doi">10.1101/mcs.a002097</pub-id><pub-id pub-id-type="pmid">29162653</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC40">
<mixed-citation publication-type="journal"><string-name><surname>Tsukamoto</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Yokota</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujiki</surname>
<given-names>Y</given-names></string-name>. <year>1990</year>
<article-title>Isolation and characterization of Chinese hamster ovary cell mutants defective in assembly of peroxisomes</article-title>. <source/>J Cell Biol
<volume>110</volume>: <fpage>651</fpage>–<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.110.3.651</pub-id><pub-id pub-id-type="pmid">1689731</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC41">
<mixed-citation publication-type="journal"><string-name><surname>Wanders</surname>
<given-names>RJ</given-names></string-name>. <year>2004</year>
<article-title>Metabolic and molecular basis of peroxisomal disorders: a review</article-title>. <source/>Am J Med Genet A
<fpage>355</fpage>–<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.20661</pub-id><pub-id pub-id-type="pmid">15098234</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC42">
<mixed-citation publication-type="journal"><string-name><surname>Wanders</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Waterham</surname>
<given-names>HR</given-names></string-name>. <year>2006</year>
<article-title>Biochemistry of mammalian peroxisomes revisited</article-title>. <source/>Annu Rev Biochem
<volume>75</volume>: <fpage>295</fpage>–<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.biochem.74.082803.133329</pub-id><pub-id pub-id-type="pmid">16756494</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC43">
<mixed-citation publication-type="journal"><string-name><surname>Waterham</surname>
<given-names>HR</given-names></string-name>, <string-name><surname>Ebberink</surname>
<given-names>MS</given-names></string-name>. <year>2012</year>
<article-title>Genetics and molecular basis of human peroxisome biogenesis disorders</article-title>. <source/>Biochim Biophys Acta
<volume>1822</volume>: <fpage>1430</fpage>–<lpage>1441</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2012.04.006</pub-id><pub-id pub-id-type="pmid">22871920</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC44">
<mixed-citation publication-type="journal"><string-name><surname>Weller</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gould</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Valle</surname>
<given-names>D</given-names></string-name>. <year>2003</year>
<article-title>Peroxisome biogenesis disorders</article-title>. <source/>Annu Rev Genomics Hum Genet
<volume>4</volume>: <fpage>165</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.genom.4.070802.110424</pub-id><pub-id pub-id-type="pmid">14527301</pub-id></mixed-citation>
</ref>
<ref id="MCS003483TANC45">
<mixed-citation publication-type="journal"><string-name><surname>Weller</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cajigas</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Morrell</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Obie</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Steel</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gould</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Valle</surname>
<given-names>D</given-names></string-name>. <year>2005</year>
<article-title>Alternative splicing suggests extended function of <italic>PEX26</italic> in peroxisome biogenesis</article-title>. <source/>Am J Hum Genet
<volume>76</volume>: <fpage>987</fpage>–<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1086/430637</pub-id><pub-id pub-id-type="pmid">15858711</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>